Download file | Play in new window | |
Prostate cancer screening recommendations and treatment approaches have varied significantly since the early 2000s. Current guidelines recommend regular prostate-specific antigen (PSA) testing for men in their 40s and 50s, depending on their other risk factors and conversations with their doctors. While interventions after an elevated PSA were formally aggressive, including immediate biopsy and surgery, today urologists use additional testing to determine when invasive procedures are truly necessary. In some cases, the best treatment may simply be monitoring a low-risk cancer over time.
As a primary care doctor, I have a little saying in the office: When I refer to specialists, I want them to do special things.
My recent conversation with Dr. Ben Dehner reminded me just how fortunate we are to have relationships with specialists who more than live up to that hope.
Dr. Dehner is a board-certified urologist who founded Nashville Urology after nearly a decade of clinical practice. A leader in modern urology and surgical innovation, he demonstrates a passionate commitment to advancing patient care and outcomes. That commitment resonates with me and gives me confidence that any patient I refer his way is in excellent hands.
While Dr. Dehner treats a wide range of urological issues, we focused this first discussion on one specific but far-reaching issue that affects men everywhere: prostate cancer.
Unlike other cancers, prostate cancer holds the interesting distinction of having widely varying screening and treatment recommendations over the last 20 years. I asked Dr. Dehner to share why that is, what the current recommendations are, and what each of us can do to protect our health.
Understanding Your Prostate Cancer Risk
Prostate cancer is extremely common. Over 330,000 men will be diagnosed this year in the United States alone. Although prostate cancer can be serious, Dr. Dehner emphasizes that the vast majority of men who receive a prostate cancer diagnosis will not die from it.
In fact, they may not need treatment at all. But more on that later.
Knowing your risk factors and getting appropriate screenings gives you the best tools to make decisions early, when catching prostate cancer makes the most difference in your long-term health. With prostate cancer, the greatest risk factors are mostly outside of your control, such as:
- Age. The longer you’re on this planet, the higher your risk of prostate cancer climbs.
- Ancestry. Men in the Black community carry a higher statistical risk, as do men in the Ashkenazi Jewish population. Men with a father or brother who has had prostate cancer also have increased risk.
- Genetics. If a man carries the BRCA2 mutation, which we can determine through genetic testing, his risk of prostate cancer rises substantially, even without a personal or family history of the disease.
Though you can’t change them, understanding these risk factors still benefits you. In fact, Dr. Dehner says this is where personalized primary care is so valuable. If your father was diagnosed with prostate cancer young, for example, your doctor may suggest having you screened for the BRCA2 mutation rather than sticking only to standard screenings. Or they may have you start prostate cancer screening at an earlier age than the standard recommendation.
Knowing the risk factors enables you to have proactive conversations with your primary care physician long before you’d ever see a specialist.
From PSA to Biopsy: A More Measured Path
Today, the recommended screening for prostate cancer is the prostate-specific antigen (PSA) test. This simple blood test informs us of rising or elevated levels of the PSA protein, which is made by the prostate gland.
For years, an elevated PSA test led almost automatically to a prostate biopsy. Then the pendulum swung the other way, and PSA screening fell out of favor entirely. Dr. Dehner says neither extreme served patients well. He describes the current approach as a middle ground built on better information.
Now, instead of sending every patient with elevated levels for a biopsy, doctors consider the patient’s risk based on how elevated a PSA is, as well as other factors.
There is no single PSA cutoff that reliably separates cancer from noncancerous conditions. Doctors interpret the result in the context of age, prior results, prostate size, family history, and other findings. An elevated PSA can reflect cancer, but it can also result from benign enlargement or inflammation. An enlarged prostate, prostatitis, or even cycling or weightlifting can raise the number into this middle range. A patient with a highly elevated reading, however, such as in the 50s, 100s, or even 1000s, will likely need a biopsy regardless of other considerations.
To determine whether mid-range cases require a biopsy, though, Dr. Dehner often orders an inexpensive urine test to analyze mRNA markers. Rather than jumping straight to biopsy, this gives both doctor and patient a clearer statistical picture of actual risk.
If more clarity is needed, an MRI can help. Results are graded on the PI-RADS scale, from one to five. A score of one or two indicates a very low likelihood of cancer, while five carries roughly an 80% likelihood, though even that isn’t a certainty. MRIs can “see” many kinds of abnormalities, but they can’t definitively say whether they’re cancer, which is why we move to biopsy if indicated.
In Dr. Dehner’s practice, a biopsy is typically a quick, in-office procedure. Patients are given Valium and nitrous oxide for comfort, and he collects around 12 tissue samples from across the prostate in about five minutes. Results, graded with a Gleason score from six to ten, come back a week or two later. A score of six is the least aggressive, seven is intermediate, and eight through ten signal more serious disease.
Regardless of score, every sample also goes through additional genetic testing to assess the patient’s future risk. This newer testing helps doctors determine whether a benign result might develop into cancer later or whether an existing cancer will progress or spread.
Prostate Cancer Treatment: No More One Size Fits All
Twenty years ago, a Gleason six diagnosis nearly always meant immediate surgery or radiation. Today, Dr. Dehner and his colleagues recommend that path less often. The reason comes down to weighing the actual risk of the cancer against the real costs and risks of treatment, including erectile dysfunction, incontinence, and the burden surgery places on the patient’s family.
Genetic testing of the cancer itself now helps determine whether a low Gleason score truly behaves like a low-risk cancer or carries a higher chance of progression. That distinction shapes the recommendation. A single sample with a low Gleason score and reassuring genetics signals the person is likely an excellent candidate for active surveillance rather than treatment. Multiple samples with more concerning genetic markers, even at a low Gleason score, may call for more active intervention.
For higher-grade cancers, surgery often remains the first step, sometimes followed by radiation or hormone therapy. But even here, the field is moving toward personalization, matching the treatment to the individual rather than taking a one-size-fits-all approach.
When No Treatment Is the Best Treatment
In some cases, though prostate cancer is present, it may not require treatment.
Prostate cancer often isn’t aggressive or, as mentioned above, life-threatening. Most men, then, who receive a prostate cancer diagnosis aren’t facing a threat to how long they’ll live. The real question is how to protect the quality of that life.
“This may be your disease, but it doesn’t define you,” Dr. Dehner says.
For slow-growing cancers, monitoring may be the best course for a patient. It avoids or delays the risks of surgery while ensuring the cancer doesn’t have a chance to spread unchecked. More conservative interventions than surgery may also be an option, such as radiation and hormone therapies.
Testosterone and Prostate Cancer: Separating Fact From Fear
Dr. Dehner was taught, as many physicians once were, that testosterone caused prostate cancer. However, current research tells a different story: Testosterone doesn’t cause prostate cancer, but it can accelerate a cancer that already exists even at a subclinical level.
This doesn’t mean testosterone therapy is off the table for everyone, but it does raise the importance of monitoring. Dr. Dehner’s youngest prostatectomy patient was 36 years old, diagnosed following a rapid PSA rise after two years on testosterone therapy without proper surveillance. It’s likely he still would have developed the cancer even without the testosterone therapy, but perhaps not for another decade or more.
For men with a low-grade, monitored cancer, some research suggests that only a small amount of testosterone will saturate the cancer’s available receptors. Anything beyond that threshold simply improves quality of life without meaningfully raising risk. The key, as with so much of this conversation, is moving forward with proper guidance and consistent PSA monitoring.
Prostate Cancer: The Future Is Patient-Centered
Dr. Dehner is seeing genetic screening grow more advanced, to the point where he believes it could become part of a primary care physician’s process before even referring a patient to a specialist. He’s also closely watching newer treatments, like HIFU, laser ablation, and targeted gene therapies, to find which are effective and which fall short. He’s particularly interested in the progress of gene manipulation techniques and how they might advance to make surgery obsolete in the treatment of prostate cancer.
We closed our conversation on a point Dr. Dehner returns to again and again: “The way we’re going in medicine, especially with cancer, has to be patient-centered and has to be based upon that person in that room at that point.”
That’s the same philosophy we practice every day at Brentwood MD. Your prostate cancer risk, your Gleason score, and your genetics are unique to you, even when they resemble someone else’s on paper. A friend’s treatment plan was built for a friend’s biology, not yours. If you have questions about your own risk, your PSA history, or whether it’s time to start screening, we’re here to walk through it with you and connect you with specialists who, as I like to say, do special things.


Dr. Wright joined Brentwood MD in 2022 as the model allows him to spend more time connecting with patients and build a foundation of exceptional care. He is a Nashville native and completed his family medicine residency at the University of Tennessee Health Science Center, where he also served as Chief Resident. He believes that your health deserves a prominent position on your priority list, and would be honored to serve you and your family.






